JP2021534106A5 - - Google Patents

Info

Publication number
JP2021534106A5
JP2021534106A5 JP2021506663A JP2021506663A JP2021534106A5 JP 2021534106 A5 JP2021534106 A5 JP 2021534106A5 JP 2021506663 A JP2021506663 A JP 2021506663A JP 2021506663 A JP2021506663 A JP 2021506663A JP 2021534106 A5 JP2021534106 A5 JP 2021534106A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
independently selected
pharmaceutically acceptable
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021506663A
Other languages
English (en)
Japanese (ja)
Other versions
JP7447080B2 (ja
JP2021534106A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/045426 external-priority patent/WO2020033490A1/en
Publication of JP2021534106A publication Critical patent/JP2021534106A/ja
Publication of JP2021534106A5 publication Critical patent/JP2021534106A5/ja
Application granted granted Critical
Publication of JP7447080B2 publication Critical patent/JP7447080B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021506663A 2018-08-08 2019-08-07 Pad4阻害剤としての置換チエノピロール Active JP7447080B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862715834P 2018-08-08 2018-08-08
US62/715,834 2018-08-08
PCT/US2019/045426 WO2020033490A1 (en) 2018-08-08 2019-08-07 Substituted thienopyrroles as pad4 inhibitors

Publications (3)

Publication Number Publication Date
JP2021534106A JP2021534106A (ja) 2021-12-09
JP2021534106A5 true JP2021534106A5 (cg-RX-API-DMAC7.html) 2022-08-16
JP7447080B2 JP7447080B2 (ja) 2024-03-11

Family

ID=67766300

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021506663A Active JP7447080B2 (ja) 2018-08-08 2019-08-07 Pad4阻害剤としての置換チエノピロール

Country Status (7)

Country Link
US (1) US11981680B2 (cg-RX-API-DMAC7.html)
EP (1) EP3833671B1 (cg-RX-API-DMAC7.html)
JP (1) JP7447080B2 (cg-RX-API-DMAC7.html)
KR (1) KR102851932B1 (cg-RX-API-DMAC7.html)
CN (1) CN112566916B (cg-RX-API-DMAC7.html)
ES (1) ES2929200T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020033490A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2956090T3 (es) 2018-08-08 2023-12-13 Bristol Myers Squibb Co Inhibidores de bencimidazol de enzimas PAD
ES2929200T3 (es) 2018-08-08 2022-11-25 Bristol Myers Squibb Co Tienopirroles sustituidos como inhibidores de PAD4
EP3833440A1 (en) 2018-08-08 2021-06-16 Bristol-Myers Squibb Company Indole and azaindole inhibitors of pad enzymes
TW202115083A (zh) * 2019-09-27 2021-04-16 大陸商南京藥捷安康生物科技有限公司 肽醯精胺酸脫亞胺酶抑制劑及其用途
CN115298175B (zh) 2020-02-06 2024-05-07 百时美施贵宝公司 可用作免疫抑制剂的大环pad4抑制剂
TW202140477A (zh) 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環pad4抑制劑
MX2022013615A (es) 2020-04-30 2022-11-16 Gilead Sciences Inc Inhibidores de macrociclo de peptidilarginina deiminasas.
CN116940578A (zh) * 2020-07-02 2023-10-24 雷密克斯医疗公司 5-[5-(哌啶-4-基)噻吩并[3,2-c]吡唑-2-基]吲唑衍生物和相关化合物作为调节剂用于剪接核酸和治疗增殖性疾病
EP4178963A1 (en) * 2020-07-02 2023-05-17 Remix Therapeutics Inc. 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
EP4267562A1 (en) 2020-12-22 2023-11-01 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
TW202233174A (zh) 2020-12-22 2022-09-01 美商基利科學股份有限公司 肽基精胺酸去亞胺酶之抑制劑
WO2023133229A2 (en) * 2022-01-05 2023-07-13 Remix Therapeutics Inc. Compounds and methods for modulating splicing
AU2023387505B2 (en) * 2022-11-24 2026-03-05 Helios Huaming Biopharma Co., Ltd. Selenium containing heterocycle compounds and use thereof
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
WO2026020127A2 (en) 2024-07-19 2026-01-22 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad2 modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2611010C2 (ru) 2012-07-26 2017-02-17 Глаксо Груп Лимитед 2-(Азаиндол-2-ил)бензимидазолы в качестве ингибиторов PAD4
WO2016185279A1 (en) 2015-05-21 2016-11-24 Glaxosmithkline Intellectual Property Development Limited Benzoimidazole derivatives as pad4 inhibitors
AR107030A1 (es) 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores aza-bencimidazol de pad4
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
CN108602812B (zh) 2015-12-22 2021-11-02 坎塞拉有限公司 可用作哺乳动物组蛋白去乙酰化酶活性的抑制剂的双环异羟肟酸类化合物
SG11201807021UA (en) * 2016-02-23 2018-09-27 Padlock Therapeutics Inc Heteroaryl inhibitors of pad4
US10703741B2 (en) 2016-07-27 2020-07-07 Padlock Therapeutics, Inc. Covalent inhibitors of PAD4
KR102502992B1 (ko) 2016-09-12 2023-02-24 패들락 테라퓨틱스, 인코포레이티드 Pad4의 헤테로아릴 억제제
JP7311228B2 (ja) 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
CN110194770B (zh) * 2018-02-26 2022-08-09 药捷安康(南京)科技股份有限公司 肽酰精氨酸脱亚胺酶抑制剂及其用途
ES2929200T3 (es) 2018-08-08 2022-11-25 Bristol Myers Squibb Co Tienopirroles sustituidos como inhibidores de PAD4
EP3833440A1 (en) 2018-08-08 2021-06-16 Bristol-Myers Squibb Company Indole and azaindole inhibitors of pad enzymes
MX2021001471A (es) * 2018-08-08 2021-04-28 Bristol Myers Squibb Co Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
ES2956090T3 (es) 2018-08-08 2023-12-13 Bristol Myers Squibb Co Inhibidores de bencimidazol de enzimas PAD

Similar Documents

Publication Publication Date Title
JP2021534108A5 (cg-RX-API-DMAC7.html)
JP2021534097A5 (cg-RX-API-DMAC7.html)
CN113365998A (zh) 用于parp抑制剂的吲哚并七元酰肟类似物
JP2021534104A5 (cg-RX-API-DMAC7.html)
JP2024543976A5 (cg-RX-API-DMAC7.html)
JP2016534134A5 (cg-RX-API-DMAC7.html)
JP2023512557A5 (cg-RX-API-DMAC7.html)
JP2017536395A5 (cg-RX-API-DMAC7.html)
JP2017526675A5 (cg-RX-API-DMAC7.html)
RU2005107314A (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью
JP2021523200A5 (cg-RX-API-DMAC7.html)
JP2013532652A5 (cg-RX-API-DMAC7.html)
RU2016118768A (ru) Композиции, пригодные для лечения расстройств, связанных с kit
JP2012519691A5 (cg-RX-API-DMAC7.html)
JP2017537940A5 (cg-RX-API-DMAC7.html)
JP2016506387A5 (cg-RX-API-DMAC7.html)
JP2019529444A5 (cg-RX-API-DMAC7.html)
JP2003519102A5 (cg-RX-API-DMAC7.html)
JP2017508816A5 (cg-RX-API-DMAC7.html)
JP2009504748A5 (cg-RX-API-DMAC7.html)
JP2025505200A5 (cg-RX-API-DMAC7.html)
RU2008100019A (ru) Способ лечения чрезмерной дневной сонливости (варианты)
JP2022526220A5 (cg-RX-API-DMAC7.html)
JP2022527025A5 (cg-RX-API-DMAC7.html)
CN109790145A (zh) 二氢嘧啶类化合物及其制备方法和用途